VIVE (Viveve Medical) Debt-to-Equity: 4.97 (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VIVE Viveve Medical Inc VIVE
12 GF Score
Price $0.00
View Full Analysis

What is Viveve Medical Debt-to-Equity?

Viveve Medical VIVE 12 Debt-to-Equity is 4.97 as of Sep. 2022. GuruFocus rates VIVE with a GF Score™ of 12/100.

Viveve Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $5.88 Mil. Viveve Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.00 Mil. Viveve Medical's Total Stockholders Equity for the quarter that ended in Sep. 2022 was $1.18 Mil. Viveve Medical's debt to equity for the quarter that ended in Sep. 2022 was 4.97.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Viveve Medical's Debt-to-Equity or its related term are showing as below:

VIVE's Debt-to-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.23
* Ranked among companies with meaningful Debt-to-Equity only.

Viveve Medical  (OTCPK:VIVE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Viveve Medical Debt-to-Equity Related Terms

Viveve Medical Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Viveve Medical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viveve Medical Debt-to-Equity Chart

Viveve Medical Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.13 6.22 0.26 0.86 0.36

Viveve Medical Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.36 0.54 1.08 4.97

VIVE vs NNMX, LHDXQ, ABT: Debt-to-Equity Comparison

For the Medical Devices subindustry, Viveve Medical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viveve Medical Debt-to-Equity vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Viveve Medical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Viveve Medical's Debt-to-Equity falls into.


VIVE
12GF Score
Viveve Medical Inc VIVE
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viveve Medical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Viveve Medical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.225 + 5.124) / 15.066
=0.36

Viveve Medical's Debt to Equity Ratio for the quarter that ended in Sep. 2022 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(5.881 + 0) / 1.184
=4.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 4.97 mean?
Viveve Medical (VIVE) has a Debt-to-Equity of 4.97 as of Sep. 2022. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Viveve Medical and its competitors.
Is Viveve Medical's Debt-to-Equity too high?
Viveve Medical's current Debt-to-Equity is 4.97. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Viveve Medical's value of 4.97 is 2060.9% above this industry median. Overall, Viveve Medical has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Viveve Medical's Debt-to-Equity compare to NNMX and LHDXQ?
Viveve Medical's Debt-to-Equity of 4.97 can be compared against companies in the Medical Devices & Instruments industry. The industry median Debt-to-Equity is 0.23. Viveve Medical's value of 4.97 is 2060.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viveve Medical's current Debt-to-Equity of 4.97 is 2060.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Viveve Medical and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viveve Medical's current Debt-to-Equity is 4.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viveve Medical stock overvalued right now?
Viveve Medical (VIVE) has a current Debt-to-Equity of 4.97. The current Debt-to-Equity is 4.97 and 2060.9% above the Medical Devices & Instruments industry median of 0.23. Viveve Medical's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Viveve Medical (VIVE), the current Debt-to-Equity is 4.97 as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viveve Medical Business Description

Address 345 Inverness Drive South, Building B, Suite 250, Englewood, CO, USA, 80112
Viveve Medical Inc designs, develops, manufactures and markets a platform medical technology. Its Cryogen-cooled Monopolar Radiofrequency technology is delivered through a radiofrequency generator, handpiece and treatment tip, called the Viveve System. The Viveve System is for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The Viveve System is indicated for use and being marketed for use in general surgical procedures for electrocoagulation and hemostasis in the United States. It has a business presence in the US, Asia Pacific, Canada, Europe and Middle East and Latin America.
12GF Score

Get the complete analysis for VIVE

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price